1	Full Title: High measles and rubella vaccine coverage and seroprevalence among Zambian children				
2	participating in a measles and rubella supplementary immunization activity				
3					
4	Short title: Measles and rubella vaccination coverage and seroprevalence during an SIA				
5					
6					
7	Christine Prosperi ^{*1} , Shaun A. Truelove ^{*1,2} , Andrea C. Carcelen ^{*1} , Gershom Chongwe ³ , Francis D.				
8	Mwansa ⁴ , Phillimon Ndubani ⁵ , Edgar Simulundu ⁵ , Innocent C. Bwalya ³ , Mutinta Hamahuwa ⁵ , Kelvin				
9	Kapungu ³ , Kalumbu H. Matakala ⁵ , Gloria Musukwa ⁵ , Irene Mutale ³ , Evans Betha ³ , Nchimunya				
10	Chaavwa ⁵ , Lombe Kampamba ³ , Japhet Matoba ⁵ , Passwell Munachoonga ⁵ , Webster Mufwambi ³ , Ken				
11	Situtu ³ , Phillip E. Thuma ⁵ , Constance Sakala ⁴ , Princess Kayeye ⁴ , Amy K. Winter ^{2,6,7} , Matthew J Ferrari ⁸ ,				
12	William J. Moss ^{1,2} , Simon Mutembo ¹				
13					
14	Affiliations:				
15	1. Department of International Health, International Vaccine Access Center, Johns Hopkins				
16	Bloomberg School of Public Health, Baltimore, Maryland, USA				
17	2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore,				
18	Maryland, USA				
19	3. Tropical Diseases Research Center, Ndola, Zambia				
20	4. Government of the Republic of Zambia, Ministry of Health, Lusaka, Zambia				
21	5. Macha Research Trust, Choma, Zambia				
22	6. Department of Epidemiology and Biostatistics, University of Georgia, Athens, Georgia, USA				
23	7. Center for the Ecology of Infectious Diseases, University of Georgia, Athens, Georgia, USA				
24	8. Center for Infectious Disease Dynamics, Pennsylvania State University, State College,				
25	Pennsylvania, USA				
26					
27	*Contributed equally				
28	Corresponding author: Shaun A. Truelove (shauntruelove@jhu.edu)				
29					
30					

31 Abstract

32	Post-campaign coverage surveys estimate the number and proportion of previously unvaccinated		
33	children vaccinated during a supplementary immunization activity (SIA) but cannot address whether		
34	susceptible children seronegative to measles and rubella viruses were vaccinated during the SIA.		
35	We conducted a cross-sectional serosurvey nested within the November 2020 measles-rubella		
36	SIA in Zambia. Children aged 9 months to 5 years were systematically sampled at 30 SIA sites in Chom-		
37	and Ndola Districts. A questionnaire was administered to the caregiver to collect the child's demographi		
38	information and history of routine measles-rubella (MR) vaccination, and dried blood spot specimens		
39	were collected from the child. Specimens were tested for Immunoglobulin-G antibodies to measles and		
40	rubella viruses by enzyme immunoassay.		
41	Among children enrolled with MR vaccination data (N=2,364), 2,214 (94%) reported at least one		
42	routine MR dose before the SIA. We estimate 5.0% (118/2364) of children would not have otherwise		
43	received routine MR dose 1 without the SIA and 23.4% (553/2364) would not have otherwise received		
44	routine MR dose 2. Thus, 1 in 3.5 doses were given to an MR un- or under-vaccinated child who may no		
45	have received that dose in the absence of an SIA. Eighty-six percent of children were measles		
46	seropositive and 90% were rubella seropositive before vaccination during the SIA. Thirty-six percent of		
47	children with no prior routine MR dose were measles seropositive while nine percent of children with tw		
48	prior routine MR doses were measles seronegative.		
49	Although children vaccinated during this SIA were highly likely to already have received routine		
50	vaccinations, the SIA reached a considerable number of susceptible children. Monitoring SIA		
51	effectiveness and efficiency is important to understand the benefits of vaccine delivery strategies in		
52	reaching un- and under-vaccinated children and may guide alternative strategies.		
53			

54 Introduction

55 Despite widespread measles vaccination, measles outbreaks and endemic measles virus transmission 56 continue, resulting in an estimated 9.2 million cases and 136,000 deaths globally in 2022 [1]. To address 57 the challenge of reaching every child with measles vaccine, many countries rely on national supplemental 58 immunization activities (SIAs), mass vaccination campaigns that target all individuals within a defined 59 age range regardless of prior vaccination status. However, measles and rubella SIAs may largely provide 60 additional doses to children already vaccinated through the routine immunization program, particularly in 61 countries with high routine immunization coverage [2]. Children who are not reached by routine 62 immunization services and are unvaccinated against measles, referred to as measles zero-dose children, 63 comprise a vulnerable population who must be reached during an SIA. In addition, 5 to 15% of children 64 do not develop protective immunity following receipt of their first dose of measles-containing vaccine 65 (MCV) [3-5]. This population of children who either do not receive measles vaccine through the routine 66 immunization system or do not develop protective immunity following vaccination form the pool of 67 susceptible children.

68

69 Little is known about the proportion of susceptible children vaccinated during MR SIAs. Post-campaign 70 coverage surveys, conducted shortly after an SIA, estimate the number of zero-dose, previously 71 unvaccinated children vaccinated during the SIA but cannot address whether the SIA vaccinated 72 susceptible children who were seronegative to measles and rubella viruses. Understanding whether 73 susceptible children are vaccinated during the SIA can demonstrate the added value of SIAs in closing 74 population immunity gaps.

75

Serosurveys identify seronegative children and highlight population immunity gaps [6, 7]. However, they
can be expensive and logistically challenging to conduct [8, 9], especially when designed as communitybased serosurveys with substantial personnel and transportation costs. Conducting such surveys can be

even more difficult in resource-limited settings. Vaccine delivery platforms such as SIAs establish
centralized locations where children in the age group of interest for MR serosurveys present, reducing the
resources required to enroll children but acknowledging that children not participating in the SIA are not
included in the serosurvey. To our knowledge, there is no published literature on measles and rubella
serosurveys nested within an SIA, although integrated delivery of other interventions, such as vitamin A
supplementation and deworming, is common and has not been shown to negatively impact vaccine
coverage [10].

86

87 Zambia has a strong childhood vaccination program with 93% coverage in 2019 for the first dose of 88 measles-rubella (MR) vaccine but only 66% for the second dose [11]. The Zambian Ministry of Health 89 also has a long history of successful SIAs, reaching over 3 million children with MR vaccines during 90 Child Health Week in November 2020 [12]. However, measles outbreaks subsequently were reported in 91 several districts in 2022 and 2023, possibly due to lower than optimal coverage of the November 2020 92 MR vaccination campaign and disruptions to the routine immunization program in 2020-2021 due to the 93 COVID-19 pandemic [13, 14]. Since the impact of SIAs on population immunity cannot be adequately 94 determined by vaccination coverage estimates alone, we conducted a MR serosurvey nested within the 95 SIA to estimate the proportion of susceptible children vaccinated during the November 2020 MR SIA in 96 Zambia.

97

98 Materials and Methods

99 Overview of study design and setting

100 We conducted a descriptive cross-sectional serosurvey nested within the November 2020 MR SIA that

101 was part of Child Health Week activities in Zambia. The serosurvey was conducted in two districts, Ndola

102 District, Copperbelt Province in the northern zone of the country, which is primarily urban and had 87%

- 103 routine MCV1 coverage in 2019, and Choma District, Southern Province in the southern zone of the
- 104 country, which is primarily rural and had 90% routine MCV1 coverage in 2019.

105 Survey setting

106 In each district, we purposefully selected 10 MR SIA vaccination sites. The selected sites included a mix 107 of rural health centers, urban health centers, hospital-affiliated health center, and health posts. Health 108 Facility- and community-level characteristics were obtained for each facility with input from the site staff. 109 These characteristics included geographic location and setting (urban versus rural), type of health facility, 110 size of the health facility catchment area, functionality of the health facility based on national 111 performance metrics, and details on accessibility of the health facility or difficult to reach subpopulations 112 in the catchment area. The study team manually reviewed the list of health facilities and characteristics to 113 purposefully select 10 health facilities per district to capture the range of characteristics. Five facilities in 114 each district were selected to have serosurvey enrollment at both fixed and outreach posts, for a total of 115 30 campaign sites between the two districts. For facilities with multiple outreach sites, the survey teams 116 moved with the vaccination team to the different locations where possible; otherwise, sites expected to 117 have the most children during the campaign were selected.

118 The serosurvey teams were embedded in the campaign activities at each campaign site and recruited 119 children for the serosurvey immediately following vaccination. Children aged 9 months to 5 years who 120 were vaccinated at the selected campaign sites were systematically sampled for the serosurvey, with 121 sampling designed to enroll a similar number of participants at each health facility and distribute 122 enrollment across the days of the campaign [15]. Daily enrollment caps and sampling intervals were set 123 based on the SIA microplan and the number of children expected to be vaccinated per day. Children were 124 enrolled in the study over the six days to capture variation in the population and vaccination status. The 125 estimated sample size was 1,200 children in each district (maximum of 2,400 children), based on an

expected measles seroprevalence of 80% and 5% precision, with a type I error of 0.05, design effect of2.1 and non-response rate of 35%.

The survey team approached families of children who were systematically sampled after vaccination to introduce the serosurvey and obtain parental permission. After obtaining written informed consent from the parent or guardian of each child, demographic and vaccination history data were collected using a standardized questionnaire on a tablet-based application (REDCap Mobile). Data were uploaded daily during the campaign and reviewed to provide near real-time feedback on data quality concerns and to inform the systematic sampling procedures for the next day. The recruitment period for the study was from November 23 to November 29, 2020.

135 Specimen collection and testing

Blood was collected by finger prick using a retractable lancet and spotted onto Whatman 903 filter paper
as a dried blood spot (DBS) by trained survey staff. DBS specimens were dried for a minimum of 15 to
30 minutes then wrapped in a sealed plastic bag with a desiccant. Specimens were dried overnight,
repackaged with desiccants in sealed plastic bags, and then stored at -20 °C at the research institute's
laboratory until testing.

Dried blood spot samples were eluted according to the manufacturer's protocol and tested for antimeasles virus and anti-rubella virus IgG antibodies using a commercial enzyme linked immunoassay
(Euroimmun, Perkin Elmer, Germany) following manufacturer recommendations. Equivocal samples
were retested and the repeat result was treated as final. See Supplemental Methods for additional details
on testing procedures.

146 A stratified random subsample of 300 DBS specimens was selected from those collected in Ndola District

147 and shipped to the Centers for Disease Control and Prevention (CDC) laboratory in Atlanta, Georgia,

148 USA and tested in the CDC's Viral Preventive Diseases Branch using their multiplex bead assay (MBA)

[16]. An adjustment to the measles quantitative results was calculated by comparing the MBA and EIA
results then applied to the measles quantitative results for all specimens tested by EIA (see S1 Appendix).
For the primary analysis we used the measles MBA threshold (153 mIU/ml) to define measles
seropositivity [16, 17].

153 Statistical analyses

154 We described the demographic characteristics of enrolled children then summarized vaccination status 155 based on the number of routine MR vaccine doses received prior to the SIA according to the vaccination 156 card or caregiver recall if the card was unavailable. Children with unknown vaccination receipt based on 157 recall were excluded from vaccination-related analyses. Estimates of measles-rubella vaccine dose 1 158 (MR1) and dose 2 (MR2) vaccination status among children 12 to 23 months of age and 24 to 35 months 159 of age, respectively, were compared with 2020 estimates from WHO-UNICEF (WUENIC) [11]. 160 Associations between vaccination status and day of the SIA and other child-level characteristics were 161 explored using logistic regression. Predicted probability of MR1 at 12 months, or MR2 at 24 months, was 162 estimated for each of the 30 SIA sites using district-specific logistic regression models adjusted for age in 163 years to account for differences in age distribution by SIA site. Measles and rubella seroprevalence were 164 estimated with 95% Wald confidence intervals. Associations between measles seropositivity and child-165 level characteristics were explored using logistic regression. Analyses were conducted using R (version 166 4.2.1).

167 Effectiveness and efficiency of vaccination activities

To assess ability of the SIA to reach children that needed vaccination, we defined two novel metrics, the vaccination activity effectiveness and vaccination activity efficiency. Vaccine activity effectiveness represents the ability of the SIA to proportionately reach MR un- and under-vaccinated children in the population, as compared to a random selection of individuals in that population. It is defined as an odds

172 ratio (OR), ranging from 0 to infinity, and is calculated as the ratio of the odds of a child included in the 173 vaccination activity having received a routine dose to the odds of a child in the general population having 174 received the same routine dose. An OR=1 can be interpreted as the SIA capturing a random selection of 175 the population targeted by the SIA. As the OR moves from 1 to 0, vaccine activity effectiveness declines, 176 indicating the SIA is oversampling from previously vaccinated children, and as the OR moves from 1 to 177 infinity, vaccine activity effectiveness improves, indicating the SIA is reaching more un- or under-178 vaccinated children than a random selection.

179 Vaccine activity efficacy represents how many doses it takes the SIA to capture a single un- or under-180 vaccinated child who would not have otherwise received routine MR doses, adjusting for age and routine 181 vaccination in that population. It is defined as a proportion, ranging from 0 to 1, and is calculated as the 182 total number of administered SIA doses that went to children who otherwise would never have received 183 each routine MR dose, divided by the total number of administered SIA doses. We estimate this for each 184 dose (i.e., MR1 and MR2) by first estimating probability of having been vaccinated by each age-month 185 from the 2018 Demographic and Health Survey data for each district [18]. We then used these to estimate 186 the probability that a child will still be vaccinated, assuming they have not yet by each age, what we are 187 calling the "hazard of vaccination". We then assign a hazard to each individual in the study population 188 given their age; children who already received the dose are assigned a probability of 1. Averaging these 189 probabilities, we get an adjusted estimate of the eventual vaccination coverage via routine systems in this 190 population, and one minus this mean hazard of vaccination gives us the vaccine activity efficacy; we also 191 can express this metric as 1 child reached per N doses given. See S1 Appendix for more information. 192 Ethical approval was obtained from the Tropical Diseases Research Center Ethics Review Committee,

and Johns Hopkins Institutional Review Board. Further regulatory approval was provided by the Zambia

194 National Health Research Authority. Written informed consent was obtained from the parent or guardian195 of each child before enrollment in the study.

196 **Results**

- 197 Over the course of six days, 2,942 children aged 9 months to 5 years were approached for enrollment
- 198 from approximately 25,088 children who received measles and rubella vaccination across the 30
- serosurvey study sites. Of those approached 2,400 (82%) were enrolled, with 1203 and 1197 enrolled
- from Ndola and Choma Districts, respectively (Table 1). Only 75% of children approached at the SIA
- sites in Choma District agreed to participate compared to 91% in Ndola District, resulting in a median of
- 202 191 and 206 enrolled daily over the six days in Choma and Ndola Districts (range: 53-377 in Choma,
- **203** 151-269 in Ndola).

204

205 Table 1. Characteristics of children enrolled in a measles and rubella serosurvey nested within a

206 measles and rubella supplementary immunization activity in Zambia, November 2020.

	Choma District (N=1197)	Ndola District (N=1203)
Enrolled/approached	1197/1606 (74.5%)	1203/1326 (90.7%)
Median age, years (IQR)	2.6 (1.7, 3.7)	2.3 (1.5, 3.5)
Maternal education		
Secondary or higher	477 (39.8%)	798 (66.3%)
Primary or less	718 (60.0%)	404 (33.6%)
Travel time to campaign site		
< 30 minutes	601 (50.2%)	921 (76.6%)
> 30 minutes	578 (48.3%)	280 (23.3%)
Routine immunization card availability	1064 (88.9%)	1107 (92.0%)
At least 1 dose of DTP	1159 (96.8%)	1183 (98.3%)
BCG receipt	1155 (96.5%)	1167 (97.0%)

207

Legend: A serosurvey was nested in a Child Health Week in Zambia in two districts in Zambia, Choma

208 and Ndola. During this serosurvey, 2,400 children were enrolled, surveyed, and had blood taken to

209 measure seropositivity to measles and rubella viruses.

210 Enrolled children had a mean age of 2.6 years (interquartile range [IQR]: 1.5, 3.6) and 51% were male.

211 Forty percent of caregivers had secondary or higher education in Choma District compared to 66% in

- 212 Ndola District. Three-quarters of children enrolled in Ndola District reached the SIA site within 30
- 213 minutes, compared to only half in Choma District, consistent with a more rural setting.

214 Vaccination status

215

Of the 2,400 children enrolled in the serosurvey, 2,171 (90%) had an under-5 vaccination card. Receipt of
BCG and at least 1 DTP dose by under-5 card or parental recall was 97% and 98%, respectively, similar
to the 97% coverage estimates for the respective provinces from the Zambian Demographic and Health
Survey (DHS) [18]. Thirty-six children (1.5%) had unknown vaccination status and were treated as
missing data and excluded from vaccination-related analyses. Twenty-two percent of caregivers reported

their child's routine vaccinations were delayed due to the COVID-19 pandemic.

222

223 Among children enrolled with MR vaccination data (n=2,364; 98.5%), 94% (n=2,214) reported at least 224 one MR dose before the SIA, either via card (n=2,012; 91%) or recalled by their caregiver (n=202; 9%). 225 Children reporting no MR doses prior to the SIA (n=150) were proportionally dominated by those just 226 eligible for routine receipt, with the proportion of children with no prior MR doses decreasing with age: 227 44% (83/187) of children 9-11 months, 5% (35/735) of those 12-23 months, and 2% (32/1442) of those 228 older than 23 months had no prior MR dose (Fig 1). The median age of routine MR1 receipt was 9.5 229 months [IQR: 9.2, 10], while the median age of children receiving MR1 through the SIA was 11 months 230 (IQR: 9.6, 20.8) (S1 and S2 Figures). Additionally, 62% (1,456/2,364) reported two MR doses prior to the 231 campaign, either via card (n=1292; 89%) or recalled by their caregiver (n=164; 11%). Similar to MR1, 232 the proportion of children missing the second dose decreased with age, with 94% (421/446) of children 233 aged 9-17 months, 38% (137/358) of children 18-23 months, 14% (80/554) of children 24-35 months, and 234 14% (120/856) of children older than 35 months not having received MR2. The median age of routine 235 MR2 receipt was 18.7 months (IQR 18.3, 19.3), while the median age of children receiving MR2 through 236 the SIA was 17.2 months (IQR: 13.6, 24.8) (S1 and S2 Figures).

237

Fig 1. Number of measles-containing vaccine doses received prior to the SIA, Choma and Ndola, Zambia, November 2020.

240 Legend: The analysis was stratified by age, geographic setting, and campaign site type, and was restricted

to children >1 year. SIA type was restricted to health facilities with both fixed and outreach locations.

242

243 Of children 12-23 months, 95% received at least 1 dose of MR vaccine prior to the SIA whereas 84% of 244 children 24-35 months received two doses of MR prior to the SIA. This MR1 coverage of 95% among 245 surveyed children attending the SIA was similar to the national estimate in 2020 (96%); however, the 246 MR2 estimate of 84% was substantially higher than the 74% national estimate [11]. Based on these prior 247 coverage estimates, we estimated the SIA to have had a moderate vaccination activity effectiveness of 248 1.53, indicating inclusion in the SIA was slightly better than a random sample of the population in terms 249 of reaching unvaccinated children. However, for MR2, we identified a high correlation between routine 250 MR2 vaccination receipt and SIA participation: children who had already received MR2 through the 251 routine system were almost twice as likely to attend the SIA than those who had not received MR2 (odds 252 ratio [OR]=1.84). This translates to a low vaccination activity effectiveness of 0.54 for MR2 (i.e., worse 253 than a random sample).

254

255 Through hazard analysis and assuming the probability of vaccination by age estimated from the 2018 256 DHS, we estimate that without the SIA, 22% (95% confidence interval [CI], 18-25%) of children with 257 zero doses prior to the SIA would have eventually received a first routine dose, and 39% (95% CI, 34-258 40%) of children with one dose would have eventually received a second routine dose, through the 259 routine immunization system. With these adjustments, we estimate 95% (95% CI, 94.8-95.2%) eventual 260 MR1 coverage and 77% (95% CI, 75-77%) MR2 coverage through routine immunization among the 261 study children seeking vaccination at the SIA. This suggests the SIA still reached children with doses who 262 would not have received them otherwise: we estimate 5.0%, or 118 of 2,364 children, would not have

otherwise received MR1 without the SIA, and 23.4% (553/2364) would not have otherwise received
MR2. This equates to a first dose *vaccination activity efficiency* of 0.05, or 1 measles unvaccinated child
reached per 20 children vaccinated by the SIA and second dose *vaccination activity efficiency* of 0.23, or
under-vaccinated child in 4.3 children vaccinated in the SIA, and an overall *vaccination activity efficiency* of 0.28, or 1 out of every 3.5 SIA doses being given to a child who otherwise would not have
gotten it.

269 There was minimal difference by district in the percentage of children with prior MR receipt (Ndola: 92% 270 and Choma: 95%). There was no difference in prior MR receipt by rural versus urban setting or type of 271 SIA site (fixed versus outreach) in either district (Fig 1, S1 Table). Those missing BCG or DTP1 were 272 more likely to be measles zero-dose at time of the SIA but this was only significant for DTP1 in Ndola 273 District (OR [95% CI], 7.9 [1.7, 26.9]) (S1 Table). Children 24 months or older attending an outreach SIA 274 site in Ndola District were almost twice as likely to be missing MR2 as those attending fixed sites (OR 275 [95% CI], 1.8 [1.0, 3.3]) (S2 Table). In both districts, having two or more siblings under 5 years of age 276 was associated with missing MR2 (OR [95% CI], Choma: 3.4 [1.1, 9.1]; Ndola: 4.0 [1.4, 10.1]. Lower 277 maternal education was also associated with missing MR2, though only significant in Choma District (OR 278 [95% CI], 1.9 [1.2, 3.0]).

279 Within each district there was variability in the number of MR doses received by SIA site (Fig 2A),

although the age of the children at each site also varied (median age range 2.0 to 3.4 years, after excluding

children 9-11 months). After adjusting for age, the predicted probability of a child having received MR1

or MR2 at a fixed age (12 months and 24 months, respectively) continued to vary by SIA site (Fig 2B).

Fig 2. Variability in MR routine vaccination status by campaign site, observed and predicted,

among children participating in the November 2020 SIA in Zambia.

- 285 Legend: (A) Observed number of doses received prior to the 2020 SIA in Choma and Ndola Districts,
- Zambia. (B) Predicted probability of receiving MR1 at 12 months and MR2 at 24 months. We estimated

district-specific predicted probability of a child 12 months of age having received MR1 or a child 24
months of age having received MR2 using a logistic regression model adjusted for age and campaign site.
The model for MR2 was restricted to children 24 months and older.

290 Variation by day of the SIA

291 Characteristics of the children enrolled varied over time, with substantial variation occurring at the district 292 level by day of enrollment (S3 Fig). The average age significantly increased over time in both districts, 293 ranging from 50% of children older than 24 months on the first day to 69% on the last day. We observed 294 variability by day in the number of siblings, maternal education, and sex of the children attending the SIA 295 in Choma District. Children with no siblings younger than 5 years of age and mothers with higher levels 296 of education were more commonly observed at the beginning and end of the SIA in Choma District (S3 297 Fig). Reported travel time to reach the SIA site varied by day of the campaign in both districts. There was 298 no association in the percentage of children with a vaccination card or those having received other routine 299 immunizations (DTP1 or BCG).

300 Since there was little variability in MR receipt by district, we combined the data to examine variability in

301 MR receipt by day. After stratifying by age group, there was no difference by day in the percent of

302 children with zero MR doses prior to the SIA except for children 12-23 months of age (Fig 3A-C).

303 Restricting to children 24 months and older with at least one prior MR dose, there was no difference in

the percentage receiving their second dose through the SIA by day (Fig 3D). In outreach sites, the

305 percentage of zero-dose children was highest on the last day of the SIA (S4 Fig).

Fig 3. Variability in vaccination status of children reached through the SIA by day and age group, November 2020, Zambia.

308 Legend: We estimated the proportion of children attending the SIA who were measles zero-dose stratified309 by day of attendance and age group. A similar analysis was performed to estimate the proportion missing

the second dose of MR among children 2 years and older who had received at least one dose prior to theSIA.

312 Measles and rubella seroprevalence

- 313 Overall, 2,061 (86%) children were measles seropositive and 2,161 (90%) children were rubella
- 314 seropositive before vaccination during the SIA. Measles seroprevalence was similar between the two sites
- 315 (Fig 4A). Measles seroprevalence was 58% (95% CI: 51-65%) among those 9 months to <1 year, 88%
- 316 (95% CI: 86%-91%) among those 1-2 years, and 88% (95% CI: 87-90%) among those older than 2 years
- 317 (Fig 4B). In Ndola District among children eligible for vaccination prior to the SIA (≥ 1 year) there was
- 318 lower rubella seroprevalence among children older than 4 years.

319 Fig 4. Measles and rubella seropositivity by district, age, and number of MR doses received,

320 November 2020, Zambia.

Legend: We estimated measles and rubella seropositivity among children attending the MR SIA in select
facilities in Ndola and Choma Districts. Analyses were stratified by district then further stratified by age
of the child and number of MR doses received prior to the SIA.

324 As expected, measles and rubella seroprevalence were significantly associated with the number of MR

325 doses received prior to the SIA (p<0.001) (Fig 4C). Measles and rubella seroprevalence were similar

between those with unknown vaccination status compared to those with at least one MR vaccine dose.

327 Findings were similar when stratified by card availability (S5 Fig), although measles and rubella

328 seroprevalence were lower among those for whom vaccination status was based on recall. Thirty-six

329 percent of children with no MR doses were seropositive for measles and 35% for rubella. Of the 57

children with no MR doses who were seropositive for either measles or rubella, 49 were seropositive for

- both measles and rubella, suggesting their vaccination status was misclassified. Nine percent of children
- 332 with two doses of MR were seronegative for measles and four percent for rubella.

333

There was no difference in seroprevalence by rural versus urban setting, type of SIA site, or day of the
SIA (S6 Fig). Children with no prior receipt of BCG vaccine and those from families with more children
under 5 years of age (Choma District only) were more likely to be measles seronegative (S3 Table).

337 **Discussion**

338 Supplementary immunization activities, often in the form of weeklong vaccination campaigns, are a 339 common and valuable tool in efforts to reach and maintain immunity levels needed to control and eliminate measles, rubella, and other vaccine preventable diseases. Countries around the world rely on 340 341 regular mass vaccination campaigns to vaccinate individuals, typically children, who either never 342 received their recommended routine vaccination or who remain susceptible despite previous vaccination 343 [19]. However, despite reliance on these costly activities, it remains largely unknown just how effective 344 and efficient mass vaccination campaigns are in different settings in reaching those children who need 345 immunization, and not just revaccinating children who are already immune. This is particularly critical for 346 measles, for which upward of 95% of the population needs to be immune to achieve and sustain 347 elimination [20].

To quantify this effectiveness and efficiency, we conducted a serological survey nested within a measles and rubella SIA in two districts in Zambia in November 2020. Measles and rubella serological surveys conducted among participants in a mass vaccination campaign provide operationally relevant insights into the vaccination status and serostatus of children at the time of vaccination during the campaign.

The SIA reached a considerable number of un- and under-vaccinated children, including 28% of enrolled children who received an MR vaccine dose they probably would not have otherwise received. However, children vaccinated during this SIA were overall highly likely to already have been vaccinated through the routine immunization system. While this is not surprising, it speaks to the need for more efficient

356 approaches, such as targeted subnational campaigns or differentiated distribution of personnel and 357 resources based on the local context, particularly for countries with high vaccination coverage with two 358 doses of MCV like Zambia. Only 6% of children reached by the campaign were previously unvaccinated 359 and, after adjusting for age and the probability of eventually receiving a routine dose, this drops to only 360 5%. While SIAs may not always be the most efficient strategy to reach unvaccinated children, they can be 361 effective mechanisms to provide a second vaccination opportunity. For this 2020 SIA in Zambia, 362 effectiveness and efficiency were mixed: we estimate 23% of doses given provided MR2 to children who 363 would have never received it otherwise. However, with 84% of SIA participants compared to 74% in the 364 general population considered fully vaccinated (2 doses among children 24-35 months), this equates to 365 children who already received MR2 being twice as likely to attend the SIA as those who were 366 undervaccinated (OR = 1.84). Serology conducted during the campaign further supported this 367 observation, with most study children measles seropositive by 1 year of age (88%). Among those 2 years 368 and older, children with fewer potential opportunities to be reached by the routine immunization system, 369 we estimated 25 children needed to be vaccinated for every 1 zero-dose child and 7 children needed to be 370 vaccinated for every under-vaccinated child [21]. 371 Despite these inefficiencies, 14% of the children reached by the SIA were measles seronegative, including 372 some who had been previously vaccinated, demonstrating the continued benefits of campaigns at helping 373 to close the population immunity gap by reaching susceptible children. Assuming 85% vaccine efficacy 374 for 1 dose, and 95% for 2 doses [3-5], we would have expected 86% of children younger than five years 375 to be seropositive for measles at the time of the SIA, aligning with the observed seroprevalence. 376 However, these results also demonstrate the shortcomings of basing susceptibility – and thereby risk 377 estimates or vaccination need decisions - purely on vaccination coverage data. In contrast to the 86%

378 seropositivity, 94% of children reported a previous dose of MR1. Further, 9% of the measles seronegative

379 children reported having previously received two doses of measles vaccine, higher than the expected 95%

380 given measles vaccine immunogenicity.

381 This study demonstrates the information that can be gained rapidly about the effectiveness of an SIA. By 382 nesting a serosurvey in the SIA we were able to quantify the impact of the SIA for reaching under- and 383 unvaccinated children as well as seronegative children. Given the common long delays to perform and 384 receive data from post-campaign coverage surveys, data collected during the campaign can be valuable to 385 track whether the campaign is effectively reaching those for whom it is needed. Further, data on age, 386 vaccination status, and serostatus of children collected at the time of campaigns or other supplemental 387 immunization activities can provide useful insight into the relative efficiency of the different vaccination 388 strategies and how efficiency may vary across settings.

This study sheds light on the characteristics most associated with being un- or under-vaccinated in these districts in Zambia. Several expected characteristics were confirmed in this population. As previously shown, lower maternal education was a strong indicator of lack of prior measles and rubella vaccination [22]. Additionally, children with multiple young siblings were also more likely to miss their second dose, indicating a high drop out among children from larger families. This flags the need to develop strategies to target larger families. These inequities in vaccination status were also identified at the national level [14].

Although we were unable to detect statistical differences in maternal and child characteristics by day of campaign, there were suggestive differences. For example, outreach sites reached more seronegative children towards the end of the campaign. The middle days of the campaign reached the most children of mothers with lower educational levels. Variability by campaign day is not typically reported but could inform the most effective days or ways to reach vulnerable children.

Zambia introduced rubella-containing vaccine during the prior nationwide SIA in 2016 [23]. The 90%
rubella seropositivity is evidence of the MR1 coverage having remained above 90% and MR2 coverage
increasing from 64% in 2017 to 81% in 2021 [18]. If national estimates are similar, this would be
sufficiently high coverage to maintain rubella incidence at low levels and provide an opportunity for

Page 18 of 25

rubella elimination in Zambia. The lower rubella seroprevalence among children 4 years of age observed
in Ndola District may reflect children who were missed by rubella-containing vaccine during the 2016
MR campaign.

408 While this study contributes to our understanding of measles vaccination status and seroprevalence 409 among children attending an MR SIA in Zambia, these findings should be considered with several 410 limitations. First, while we have substantial data for children sampled during the SIA, we do not have any 411 information on those children who did not participate in the SIA. This is an important limitation because 412 our estimates of efficiency are limited to extrapolations to overall coverage estimates for Zambia as a 413 whole and may not fully reflect these locations or this time. As such, these seroprevalence estimates may 414 not be representative of the general population. Further, as we only enrolled a relatively small sample of 415 the children attending the campaign, it is also possible that the study children do not fully represent all 416 children who attended the SIA in these districts. Finally, this study was nested in a vaccination campaign 417 that occurred during the COVID-19 pandemic and had lower coverage compared to previous SIAs, which 418 could impact who was included in our study [14]. However, we expect that the potential bias is relatively 419 small in terms of who was missed from the SIA. Measles seroprevalence was higher than in a 420 representative community study in Southern Province prior to the 2016 SIA (78%) suggesting either 421 routine immunization has improved or the population attending the SIA is more likely to be vaccinated 422 than the general population [24].

This study provides valuable insights into the effectiveness and efficiency of the 2020 MR SIA in
Zambia. Monitoring SIA effectiveness, efficiency, and equity is important to understand the benefits of
vaccine delivery strategies in reaching zero-dose and under-vaccinated children. Countries like Zambia
with high MR1 and MR2 coverage could consider tailored or targeted SIAs to better reach un- and undervaccination children.

428

429 Acknowledgments

- 430 We would like to acknowledge all the children and their parents who agreed to take part in this study. We
- 431 would also like to acknowledge the Ministry of Health and all the serosurvey staff, vaccinators, nurse in-
- 432 charges, and district health staff who contributed to the successful implementation of the project. Finally,
- 433 we acknowledge Monica Pilewskie for her support coding the transcripts from the interviews.

434 Data availability

- 435 The individual survey data were collected under data sharing agreements from Zambia Ministry of Health
- 436 and the Zambia National Health Research Authority. As per the Zambia Health Research Act, access to
- 437 data requires approval from the Zambian National Health Regulatory Authority. To obtain this access,
- 438 please contact Dr Victor Chalwe, Acting Director of the Zambia National Health Research Authority
- 439 (victor.chalwe@nhra.org.zm).

440

441 References

- 442 [1] Minta AA, Ferrari M, Antoni S, Portnoy A, Sbarra A, Lambert B, et al. Progress Toward Measles
- Elimination Worldwide, 2000-2022. MMWR Morb Mortal Wkly Rep. 2023;72:1262-8.
- 444 [2] Portnoy A, Jit M, Helleringer S, Verguet S. Impact of measles supplementary immunization activities
- 445 on reaching children missed by routine programs. Vaccine. 2018;36:170-8.
- 446 [3] Clements CJ, Strassburg M, Cutts FT, Torel C. The epidemiology of measles. World Health Stat Q.
- 447 1992;45:285-91.
- 448 [4] Orenstein WA, Markowitz LE, Atkinson WL, Hinman AR. Worldwide measles prevention. Isr J Med
- 449 Sci. 1994;30:469-81.
- 450 [5] Sudfeld CR, Navar AM, Halsey NA. Effectiveness of measles vaccination and vitamin A treatment.
- 451 Int J Epidemiol. 2010;39 Suppl 1:i48-55.
- 452 [6] Ariyarajah A, Crowcroft NS. Measles Serosurveys: A Solution in Search of the Right Problem. Front
 453 Public Health. 2021;9:539325.
- 454 [7] Winter AK, Martinez ME, Cutts FT, Moss WJ, Ferrari MJ, McKee A, et al. Benefits and Challenges
- 455 in Using Seroprevalence Data to Inform Models for Measles and Rubella Elimination. J Infect Dis.
- **456** 2018;218:355-64.
- 457 [8] Carcelen AC, Hayford K, Moss WJ, Book C, Thuma PE, Mwansa FD, et al. How much does it cost to
- 458 measure immunity? A costing analysis of a measles and rubella serosurvey in southern Zambia. PLoS
 459 One. 2020;15:e0240734.
- 460 [9] Travassos MA, Beyene B, Adam Z, Campbell JD, Mulholland N, Diarra SS, et al. Strategies for
- 461 Coordination of a Serosurvey in Parallel with an Immunization Coverage Survey. Am J Trop Med Hyg.
- **462** 2015;93:416-24.
- 463 [10] Health Campaign Effectiveness Coalition. Considerations for Integrating Health Campaigns: A
- 464 Synthesis of Findings from Implementation Research Studies in Immunization, Neglected Tropical
- 465 Diseases, Malaria, and Vitamin A Supplementation. Decatur, GA, USA2023.

- 466 [11] UNICEF, WHO. Zambia: WHO and UNICEF estimates of national immunization coverage: 2021467 revision. 2022.
- 468 [12] Fiedler JL, Mubanga F, Siamusantu W, Musonda M, Kabwe KF, Zulu C. Child Health Week in
- 469 Zambia: costs, efficiency, coverage and a reassessment of need. Health Policy Plan. 2014;29:12-29.
- 470 [13] Winter AK, Takahashi S, Carcelen AC, Hayford K, Mutale W, Mwansa FD, et al. An evaluation of
- 471 the early impact of the COVID-19 pandemic on Zambia's routine immunization program. PLOS Glob
- 472 Public Health. 2023;3:e0000554.
- 473 [14] Yang Y, Kostandova N, Mwansa FD, Nakazwe C, Namukoko H, Sakala C, et al. Challenges
- 474 Addressing Inequalities in Measles Vaccine Coverage in Zambia through a Measles-Rubella
- 475 Supplementary Immunization Activity during the COVID-19 Pandemic. Vaccines (Basel). 2023;11.
- 476 [15] Carcelen AC, Prosperi C, Hamahuwa M, Kapungu K, Chongwe G, Mwansa FD, et al. Feasibility and
- 477 acceptability of collecting dried blood spots (DBS) from children after vaccination during Supplementary
- 478 Immunization Activities to estimate measles and rubella seroprevalence. medRxiv.
- **479** 2024:2024.02.14.24302830.
- 480 [16] Coughlin MM, Matson Z, Sowers SB, Priest JW, Smits GP, van der Klis FRM, et al. Development of
- 481 a Measles and Rubella Multiplex Bead Serological Assay for Assessing Population Immunity. J Clin
- 482 Microbiol. 2021;59.
- 483 [17] Bolotin S, Hughes SL, Gul N, Khan S, Rota PA, Severini A, et al. What Is the Evidence to Support a
- 484 Correlate of Protection for Measles? A Systematic Review. J Infect Dis. 2020;221:1576-83.
- 485 [18] Zambia Statistics Agency, Ministry of Health (MOH) Zambia, ICF. Zambia Demographic and
- 486 Health Survey 2018. Lusaka, Zambia, and Rockville, Maryland, USA: Zambia Statistics Agency,
- 487 Ministry of Health (MOH) Zambia, and ICF; 2019.
- 488 [19] Organization WH. Planning and implementing high-quality supplementary immunization activities
- 489 for injectable vaccines using an example of measles and rubella vaccines: field guide. Geneva2016.

- 490 [20] Patel MK, Goodson JL, Alexander JP, Jr., Kretsinger K, Sodha SV, Steulet C, et al. Progress Toward
- 491 Regional Measles Elimination Worldwide, 2000-2019. MMWR Morb Mortal Wkly Rep. 2020;69:1700-
- **492** 5.
- 493 [21] Hashim A, Dang V, Bolotin S, Crowcroft NS. How and why researchers use the number needed to
- 494 vaccinate to inform decision making--a systematic review. Vaccine. 2015;33:753-8.
- 495 [22] Forshaw J, Gerver SM, Gill M, Cooper E, Manikam L, Ward H. The global effect of maternal
- 496 education on complete childhood vaccination: a systematic review and meta-analysis. BMC Infect Dis.497 2017;17:801.
- 498 [23] Mazaba ML, Siziya S, Monze M, Cohen D. Epidemiology of acute rubella infection in Zambia
- during the pre-vaccination period (2005-2016) as a baseline for monitoring rubella epidemiology in the
- 500 post-rubella vaccine introduction era. BMC Infect Dis. 2020;20:101.
- 501 [24] Hayford K, Mutembo S, Carcelen A, Matakala HK, Munachoonga P, Winter A, et al. Measles and
- rubella serosurvey identifies rubella immunity gap in young adults of childbearing age in Zambia: The
- 503 added value of nesting a serological survey within a post-campaign coverage evaluation survey. Vaccine.
- **504** 2019;37:2387-93.

505

506

507 Supporting information captions

508 S1 Table. Characteristics associated with not receiving measles-rubella vaccine prior to the SIA.

509 The analysis was restricted to children 12 months and older. The outcome was no MR doses prior to the

- 510 SIA. Univariable ORs were adjusted for age in years. Analysis with SIA site type (outreach vs fixed) was
- 511 restricted to health facilities with both fixed and outreach locations. Bold indicates p < 0.05.

512 S2 Table. Characteristics associated with missing the second measles-rubella vaccine dose prior to

513 the SIA among those with at least 1 dose. This analysis was restricted to children 24 months and older

- 514 with at least 1 MR dose prior to the SIA. The outcome was no receipt of the second MR dose prior to the
- 515 SIA. Univariable ORs adjusted for age in years. Analysis with SIA site type (outreach vs fixed) was
- **516** restricted to health facilities with both fixed and outreach locations. Bold indicates p < 0.05.

517 S1 Figure. Age at routine measles-rubella vaccine receipt. Children were excluded from this analysis if

518 vaccine receipt was based on recall, if the dosing date was prior to their date of birth, or if the MR2

- 519 receipt date was on or prior to the date of MR1 receipt. Remaining children with a card but no
- 520 documented evidence of MR were right-censored at 59 months.

521 S2 Figure. Age at vaccination during the SIA for children receiving their first or second measles

522 vaccine dose through the SIA. Dashed vertical lines represent anticipated age of MR1 and MR2 receipt

- 523 (MR1, 9 months and MR2, 18 months)
- 524 S3 Figure. Variability in descriptive characteristics of children by SIA day.

525 S4 Figure. Variability by day in the percentage of children with no MR doses prior to the SIA by

- 526 type of SIA site. Both districts combined. Restricted to health facilities with both fixed and outreach
- 527 locations and excluding children < 12 months. P-value for variability by day in percent zero-dose from
- **528** logistic regression model adjusted for age and district: fixed site, 0.60; outreach site, 0.07.

- 529 S5 Figure. Measles and rubella seropositivity by number of doses and card availability.
- 530 S6 Figure. Measles and rubella seropositivity by setting, SIA type, and campaign day. Analysis with
- 531 SIA site type (outreach vs fixed) restricted to health facilities with both fixed and outreach locations.
- 532 S3 Table. Characteristics associated with measles seronegativity
- 533 S1 Appendix.







0 doses 1 dose 2 doses



A. Observed number of doses





Measles Rubella